FDA Accepts Supplement Application for Artesunate by Amivas
The FDA has accepted a supplemental application for Artesunate (NDA213036) submitted by Amivas.
Asset / Drug
Drug and asset intelligence for Amivas with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.